Form 8-K - Current report:
SEC Accession No. 0001628280-23-018655
Filing Date
2023-05-17
Accepted
2023-05-17 16:01:26
Documents
15
Period of Report
2023-05-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ardx-20230517.htm   iXBRL 8-K 34751
2 EX-99.1 pressreleasemay172023.htm EX-99.1 12846
6 ardx-20230517_g1.jpg GRAPHIC 2570
7 image_0a.jpg GRAPHIC 33091
  Complete submission text file 0001628280-23-018655.txt   244380

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ardx-20230517.xsd EX-101.SCH 1899
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ardx-20230517_lab.xml EX-101.LAB 24849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ardx-20230517_pre.xml EX-101.PRE 13044
9 EXTRACTED XBRL INSTANCE DOCUMENT ardx-20230517_htm.xml XML 11233
Mailing Address 34175 ARDENWOOD BLVD. FREMONT CA 94555
Business Address 34175 ARDENWOOD BLVD. FREMONT CA 94555 510-745-7047
ARDELYX, INC. (Filer) CIK: 0001437402 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36485 | Film No.: 23931553
SIC: 2834 Pharmaceutical Preparations